|Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial|
CC Iwuji, J Orne-Gliemann, J Larmarange, E Balestre, R Thiebaut, ...
The lancet HIV 5 (3), e116-e125, 2018
|Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon …|
C Laurent, C Kouanfack, G Laborde-Balen, AF Aghokeng, JBT Mbougua, ...
The Lancet infectious diseases 11 (11), 825-833, 2011
|Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors|
S Boyer, I Clerc, CR Bonono, F Marcellin, PC Bilé, B Ventelou
Social science & medicine 72 (8), 1383-1392, 2011
|The point-of-care laboratory in clinical microbiology|
M Drancourt, A Michel-Lepage, S Boyer, D Raoult
Clinical microbiology reviews 29 (3), 429-447, 2016
|Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial …|
CC Iwuji, J Orne-Gliemann, F Tanser, S Boyer, RJ Lessells, F Lert, J Imrie, ...
Trials 14 (1), 230, 2013
|Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon|
S Boyer, F Eboko, M Camara, C Abé, MEO Nguini, S Koulla-Shiro, ...
Aids 24, S5-S15, 2010
|HIV disclosure and unsafe sex among HIV-infected women in Cameroon: results from the ANRS-EVAL study|
S Loubiere, P Peretti-Watel, S Boyer, J Blanche, SC Abega, B Spire
Social science & medicine 69 (6), 885-891, 2009
|Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey|
S Boyer, F Marcellin, P Ongolo-Zogo, SC Abega, R Nantchouang, B Spire, ...
Bulletin of the World Health Organization 87, 279-287, 2009
|Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12‐116)|
F Marcellin, S Boyer, C Protopopescu, A Dia, P Ongolo‐Zogo, ...
Tropical medicine & international health 13 (12), 1470-1478, 2008
|Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110 …|
S Boyer, L March, C Kouanfack, G Laborde-Balen, P Marino, ...
The Lancet infectious diseases 13 (7), 577-586, 2013
|The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012-2016|
C Iwuji, J Ome-Gliemann, E Balestre, J Larmarange, R Thiebaut, F Tanser, ...
Journal of the International AIDS Society 19 (5), 2016
|Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers|
S Loubiere, S Boyer, C Protopopescu, CR Bonono, SC Abega, B Spire, ...
Health policy 92 (2-3), 165-173, 2009
|Relationship between Charcot-Marie-Tooth 1A and Smith-Magenis regions. snU3 may be a candidate gene for the Smith-Magenis syndrome|
C Chevillard, DL Paslier, E Passage, P Ougen, A Billault, S Boyer, ...
Human molecular genetics 2 (8), 1235-1243, 1993
|Performance of HIV care decentralization from the patient’s perspective: health-related quality of life and perceived quality of services in Cameroon|
S Boyer, C Protopopescu, F Marcellin, MP Carrieri, S Koulla-Shiro, ...
Health policy and planning 27 (4), 301-315, 2012
|Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods|
P Roux, C Kouanfack, J Cohen, F Marcellin, S Boyer, E Delaporte, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 57, S40-S43, 2011
|Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the S tratall ANRS 12110/ESTHER trial in C ameroon|
M Meresse, L March, C Kouanfack, RC Bonono, S Boyer, ...
HIV medicine 15 (8), 478-487, 2014
|Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey)|
A Dia, F Marcellin, RC Bonono, S Boyer, AD Bouhnik, C Protopopescu, ...
Sexually transmitted infections 86 (2), 148-154, 2010
|Dolutegravir-based or low-dose Efavirenz–based regimen for the treatment of HIV-1|
NAMSAL ANRS 12313 Study Group
New England Journal of Medicine 381 (9), 816-826, 2019
|Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal|
J Orne-Gliemann, J Larmarange, S Boyer, C Iwuji, N McGrath, ...
BMC public health 15 (1), 209, 2015
|Gender differences in adherence and response to antiretroviral treatment in the Stratall trial in rural district hospitals in Cameroon|
C Boullé, C Kouanfack, G Laborde-Balen, S Boyer, AF Aghokeng, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 69 (3), 355-364, 2015